SCN3B Gene Brugada Syndrome Type 7 Genetic Test in UAE | 2800 AED | 2026 DHA Guidelines

تحليل جين SCN3B لمتلازمة بروغادا النوع السابع في الإمارات | 2800 درهم | معتمد من هيئة الصحة بدبي

Executive Summary

Accuracy Guarantee: 99.9% Diagnostic Sensitivity via NGS technology processed in an ISO 9001:2015 (Cert: INT/EGQ/2509DA/3139) accredited laboratory. Premium Logistics: Paid Hospital-Grade Home Collection via ISO Certified Cold-Chain Home Collection and VIP Mobile Phlebotomy (8 AM – 11 PM). Clinical Guidance: Telephonic Post-Test Clinical Guidance in result interpretation with genetic counselling support. Insurance: Direct Billing Verification via WhatsApp at +971 54 548 8731.

الملخص التنفيذي

فحص جين SCN3B لمتلازمة بروغادا النوع السابع باستخدام تقنية التسلسل الجيني المتقدم (NGS) في دولة الإمارات العربية المتحدة. دقة تشخيصية بنسبة 99.9% عبر مختبر معتمد بموجب ISO 9001:2015. خدمة سحب دم منزلي على مستوى المستشفيات مع استشارة وراثية متكاملة، ودعم مباشر عبر الواتساب للتحقق من التغطية التأمينية.

Overview

The SCN3B Gene Brugada Syndrome Type 7 Genetic Test is a high-precision Next-Generation Sequencing assay that screens the SCN3B gene for pathogenic variants linked to Brugada Syndrome Type 7, a heritable cardiac channelopathy associated with elevated risk of ventricular arrhythmia and sudden cardiac death. This test is indicated for individuals with a clinical suspicion of Brugada Syndrome, a confirmed family history, or equivocal ECG findings requiring molecular confirmation for definitive diagnosis and risk stratification.

اختبار جيني متقدم لتسلسل الحمض النووي لجين SCN3B المرتبط بمتلازمة بروغادا النوع السابع، وهي حالة قلبية وراثية تزيد من خطر اضطراب النظم البطيني والموت القلبي المفاجئ.

Feature	OUR TEST SCN3B NGS (UAE)	Closest Alternative
Methodology	NGS (Next-Generation Sequencing) — Full Gene Coverage	Standard Sanger Sequencing / Limited Panel
Diagnostic Sensitivity	99.9% — ISO 9001:2015 Validated	~95% — Variable QC Standards
Turnaround Time	21–28 Days (Expedited Available)	4–8 Weeks
Genetic Counselling	Included — Pre & Post-Test	Often Not Included
Regulatory Compliance	DHA-Licensed (Facility: 9834453) \| UAE PDPL Compliant	Variable

Physician Insight & Safety Protocol

"As a clinical cardiologist with the DHA, I emphasize that a positive SCN3B variant must always be interpreted alongside a comprehensive 12-lead ECG, Holter monitoring, and detailed family history. A negative result does not exclude Brugada Syndrome, as other genes and non-genetic factors may contribute. Genetic testing is a powerful tool, but it is not a standalone verdict — clinical correlation is paramount."

— Dr. PRABHAKAR REDDY, DHA License: 61711031, Consultant Cardiologist

⚠ Medication Advisory

Do not discontinue prescribed medication without consulting your doctor. Patients with suspected or confirmed Brugada Syndrome must avoid specific agents known to unmask or exacerbate Brugada ECG patterns. A comprehensive avoidance list — including certain antiarrhythmics (Class IC), psychotropic agents, and anesthetics — will be provided in your post-test clinical report. Always inform every treating physician of your Brugada diagnosis before any surgical procedure or new prescription.

⚠ Exclusion Criteria & Emergency Red Flags

Exclusion Criteria: This test is not suitable as a standalone screening tool for asymptomatic individuals without a clinically confirmed Brugada ECG pattern (Type 1) or a documented family history of Brugada Syndrome or unexplained sudden cardiac death in a first-degree relative. Genetic testing of minors follows strict CDS Law 2026 provisions requiring parental consent and clinical justification.
Emergency Red Flags — Seek Immediate Medical Attention: Unexplained syncope (fainting), nocturnal agonal respiration, documented polymorphic ventricular tachycardia, or seizure-like episodes during sleep. These symptoms in the context of a known or suspected Brugada diagnosis constitute a medical emergency.
Data Privacy Assurance: All genetic data is processed and stored in full compliance with UAE PDPL (Federal Decree-Law No. 41 of 2024, Art. 87). Genomic information is never shared with third parties without explicit, documented consent.

Patient FAQ & Clinical Guidance

Q1: What is the SCN3B Gene Brugada Syndrome Type 7 Genetic Test, and who should consider it?

The SCN3B Genetic Test is a high-resolution molecular diagnostic assay that sequences the entire coding region of the SCN3B gene to identify pathogenic variants responsible for Brugada Syndrome Type 7, a hereditary cardiac channelopathy that predisposes individuals to life-threatening ventricular arrhythmias and sudden cardiac death — even in the absence of structural heart disease.

ما هو اختبار جين SCN3B لمتلازمة بروغادا النوع السابع، ومن ينبغي عليه إجراؤه؟

اختبار جيني تشخيصي عالي الدقة يحدد الطفرات المسببة لمتلازمة بروغادا النوع السابع، ويُنصح به للمرضى الذين لديهم تاريخ عائلي للموت القلبي المفاجئ أو تخطيط قلب يوحي بالإصابة.

Q2: How is the sample collected, and what is the turnaround time for results?

Sample collection is performed via a minimally invasive blood draw (whole blood, extracted DNA, or a single drop of blood on an FTA card) by a DHA-licensed phlebotomist during a scheduled home visit between 8 AM and 11 PM, with cold-chain transport to our ISO-certified laboratory; results are delivered within 21 to 28 days with an optional expedited processing pathway available upon request.

كيف يتم جمع العينة وما هي مدة الحصول على النتائج؟

يتم سحب عينة الدم في المنزل بواسطة مختص مرخص من هيئة الصحة بدبي، وتُرسل عبر سلسلة تبريد معتمدة إلى المختبر، وتظهر النتائج خلال 21 إلى 28 يومًا.

Q3: Is the SCN3B Brugada Syndrome genetic test covered by health insurance in the UAE?

Many UAE-based health insurance providers cover genetic testing for Brugada Syndrome when supported by a valid referral from a DHA-licensed cardiologist and documented clinical necessity; our dedicated billing team verifies your insurance eligibility via direct coordination and provides confirmation through WhatsApp at +971 54 548 8731 before any out-of-pocket expense is incurred.

هل يغطي التأمين الصحي في الإمارات اختبار جين SCN3B لمتلازمة بروغادا؟

تغطي العديد من شركات التأمين في الإمارات هذا الاختبار الجيني عند وجود تحويل طبي من طبيب قلب معتمد، ويمكن التحقق من التغطية عبر الواتساب قبل إجراء الفحص.

Pre-Test Information

A comprehensive clinical history of the patient is required prior to testing.
A pre-test genetic counselling session is mandatory to construct a detailed pedigree chart documenting all family members affected by or suspected of carrying SCN3B gene variants linked to Brugada Syndrome Type 7.
Acceptable sample types: Whole Blood (EDTA tube), Extracted DNA, or One Drop of Blood on an FTA Card.
Patients must disclose all current medications, particularly antiarrhythmics and psychotropic agents, during the pre-test consultation.

Regulatory Compliance: This service operates under Facility License No. 9834453 issued by the Dubai Health Authority (DHA). All procedures adhere to Federal Decree-Law No. 41 of 2024 (Art. 87), CDS Law 2026 provisions for minors, and the UAE Personal Data Protection Law (PDPL).

Accreditation: ISO 9001:2015 Certified — Certificate No. INT/EGQ/2509DA/3139.

Medical Disclaimer: This is a diagnostic aid and must be interpreted by a qualified, DHA-licensed cardiologist or clinical geneticist. It does not replace comprehensive cardiac evaluation, including 12-lead ECG, electrophysiology studies, or clinical risk stratification.

Contact: WhatsApp Support: +971 54 548 8731 | Home Collection Hours: 8 AM – 11 PM Daily

دعم ثنائي اللغة متاح